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SUMMARY – Diabetes mellitus type 2 is associated with greater bone mineral density (BMD) 
due to obesity, although rapid bone loss observed over time could be explained by elevated chronic 
infl ammation. Th e objective of this study was to investigate the relationship between central adiposity 
and hyperinsulinemia, as well as infl ammation markers with vertebral and femoral BMD and bone 
turnover markers in postmenopausal women with type 2 diabetes. Femoral and vertebral BMD, 
 osteocalcin, pyrilinks D, beta-CrossLaps (B-CTx), insulin, C-reactive protein (CRP), fi brinogen and 
plasminogen activator inhibitor-1 (PAI-1) were measured in 114 postmenopausal female patients 
with diabetes type 2. Th e patients of similar age, HbA1c levels and diabetes duration were divided into 
2 groups based on their body mass index (BMI) values: lower or equal to 27 kg/m2 (31 patients) and 
higher than 27 kg/m2 (83 patients). Lower levels of osteocalcin (p=0.001), B-CTx (p=0.000007) and 
pyrilinks D (p=0.0365), and higher femoral BMD (p=0.00006), insulin level (p=0.0002), PAI-1 
(p=0.00000) and CRP (p=0.002) were found in the overweight group. Th ere were no signifi cant 
 diff erences in vertebral BMD and fi brinogen. Osteocalcin and B-CTx showed inverse correlation, and 
femoral BMD positive correlation with waist circumference, insulin level and PAI-1. Th is suggests 
that abdominal obesity and hyperinsulinemia as components of the metabolic syndrome could in-
crease femoral BMD by lowering bone rate. In addition, the only infl ammation marker linked with 
femoral BMD was PAI-1, which is associated with increased mineralization of cortical bone in mouse 
models.
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Introduction
Diabetes mellitus type 2 (T2DM) can infl uence 
bone through several mechanisms, some of which may 
have contradictory eff ects. Obesity or high body mass 
index (BMI) has a protective eff ect against excessive 
bone loss with aging1-4. Th is is probably a result of 
 enhanced osteoblast diff erentiation due to heavier 
 mechanical loading of bone, whereas hyperinsuline-
mia may promote bone formation5. Higher glucose 
levels in the blood interact with several proteins ge-
nerating higher concentration of advanced glycation 
end-products (AGEs) in collagen that may reduce 
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bone strength6. Accumulated AGEs in the body may 
stimulate apoptosis of osteoblasts, thereby contribut-
ing to defi cient bone formation7.
Th e metabolic syndrome includes obesity, dyslipid-
emia, impaired glucose tolerance, and hypertension8, 
and is also associated with low-grade infl ammation, as 
well as diabetes mellitus type 2 (T2DM)9. In osteopo-
rosis, bone mineral density (BMD) is reduced and 
bone microarchitecture deteriorated, which leads to an 
increased risk of fracture10. Proinfl ammatory cytokines 
up-regulate receptor activator of nuclear factor-κB li-
gand, leading to increased bone resorption11-13. Some 
authors have suggested that elevated C-reactive pro-
tein (CRP) is associated with osteoporosis and non-
traumatic fracture14,15.
Many studies investigated the relationship between 
T2DM and bone metabolism, but their results were 
inconsistent. For patients with T2DM, some authors 
have reported increased BMD, others have reported 
decreased BMD, and some have reported unaltered 
BMD16.
Th e aim of this study was to investigate the rela-
tionship between components of the metabolic syn-
drome, central adiposity and hyperinsulinemia, as well 
as infl ammation markers with vertebral and femoral 




Th is study complied with the Declaration of Hel-
sinki and was approved by the Ethics Committee of 
the Osijek University Hospital Center. Th e subjects 
enrolled in the study were a subset of all patients hav-
ing visited or being hospitalized for regular medical 
check-up at the Department of Endocrinology and 
Diabetes, Osijek University Hospital Center. Th is 
cross-sectional study included 114 female postmeno-
pausal patients with T2DM aged ≥45 years, with simi-
lar HbA1c levels and diabetes duration, divided into 2 
groups based on their BMI values: lower or equal to 27 
kg/m2 (31 patients) and higher than 27 kg/m2 (83 pa-
tients)17. Patients with a history of the following con-
ditions were excluded from the study: those taking 
medication for osteoporosis; those receiving hormone 
replacement therapy or other medications such as glu-
cocorticoids, aff ecting BMD; those with conditions 
such as malignancy, thyroid disease or thyroid func-
tional abnormality that would be apparent causes for 
abnormal bone mass; and those with acute infectious 
disease or chronic infl ammatory diseases. BMI was 
calculated from body weight and height (kg/m2). Waist 
circumference at the bending point was measured in 
centimeters with the participant wearing only a single 
layer of clothes. Postmenopausal status was defi ned, 
through close history taking, as cessation of menstrua-
tion for at least 1 year.
BMD measurement
Bone mineral density of lumbar spine and total fe-
mur was measured by dual energy x-ray absorptiome-
try (Dexa QDR 1000, Hologic, Inc., Waltham, MA, 
USA) calibrated daily using a standard phantom pro-
vided by the manufacturer. Lumbar spine BMD was 
the mean of lumbar vertebrae 1-4.
Biochemical assay
At study entry, all women underwent blood analy-
ses to verify their healthy state. Bone metabolism was 
evaluated by determining serum levels of osteocalcin 
(OC) as a marker of bone formation, and urinary pyri-
links-D (PYD) and beta-CrossLaps (B-CTx) as mar-
kers of bone resorption18. Second morning urine sam-
ple was collected and PYD in urine was measured us-
ing competitive enzyme immunoanalysis by commer-
cially available kit, according to the manufacturer’s 
protocol (Metra Biosystem Inc., Mountain View, USA; 
reference value 3.0-7.4 nM DPD/mM creatinine). Se-
rum OC levels were assayed by an immunoradiometric 
assay (IRMA) with commercially available kits, ac-
cording to the manufacturer’s recommendations (Bio-
Source Europe S.A., Nivelles, Belgium; reference value 
5-25 ng/mL). Serum Beta-CTx was measured by elec-
trochemiluminescent immunoassay (ECLIA) by com-
mercially available kit, according to the manufacturer’s 
protocol (Roche-B-Crosslaps assay, Roche Diagnos-
tics, Mannheim, Germany). Serum insulin levels were 
determined with RIA method. Automated CRP mea-
surement was performed by immunoturbidimetry on a 
modular clinical analyzer (Olympus, Beckman Coult-
er, Inc., USA). Fibrinogen and plasminogen activator 
inhibitor-1 (PAI-1) were determined by coagulometry 
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using a BCS automated photometric coagulation ana-
lyzer (Behring Coagulation System, Marburg, Ger-
many).
Statistical analysis
Results were processed using descriptive statistical 
analysis. Continuous variables were summarized using 
sample size, mean, median, standard deviation, and 
minimum and maximum values. Signifi cance was de-
clared at a two-sided 0.05 level, unless otherwise spec-
ifi ed. Mann Whitney as a non-parametric test was 
used to calculate distribution diff erences for continu-
ous variables. Spearman’s correlation coeffi  cients were 
computed to estimate the magnitude of the associa-
tion between the variables of interest. Statistical analy-
sis was performed using StatSoft, Statistica 8.0.
Results
Baseline characteristics of the subjects are summa-
rized in Table 1. Both groups had similar diabetes du-
ration and HbA1c levels. Th ere was no signifi cant dif-
ference in vertebral BMD or fi brinogen between the 
two groups. Th e mean values of PAI-1 (p=0.000000), 
CRP (p=0.002) and insulin (p=0.0002), as well as total 
femoral BMD (p=0.00006) were signifi cantly higher, 
whereas bone turnover markers, i.e. osteocalcin (p=
0.001), B-CTx (p=0.000007) and pyrilinks D (p=
0.0365) were signifi cantly lower in the overweight 
group. Th is could suggest that bone activity was sup-
Table 1. Baseline characteristics of subjects relative to body 






Mean SD Mean SD
Waist 
circumference
88.32 8.71 99.90 9.79 0.0000
Insulin 7.61 3.45 13.36 12.78 0.0002
PAI-1 2.46 1.25 4.47 2.03 0.0000
CRP 2.86 2.99 5.54 5.87 0.0025
Fibrinogen 4.06 0.79 4.14 0.86 0.9356
Pyrilinks D 7.59 3.03 6.31 2.54 0.0365
Osteocalcin 9.61 4.53 6.77 3.40 0.0012
B-CTx 0.60 0.32 0.34 0.18 0.0003
Femoral BMD 0.78 0.13 0.91 0.13 0.0000
Vertebral BMD 0.86 0.17 0.92 0.10 0.0750
Diabetes 
duration
12.98 7.31 10.42 6.66 0.5087
HbA1c 10.11 2.23 9.63 2.17 0.8310
PAI-1 = plasminogen activator inhibitor-1; CRP = C-reactive 
protein; B-CTx = beta-CrossLaps; BMD = bone mineral density; 
HbA1c = glycated hemoglobin
Table 2. Correlation of bone mineral density and bone turnover markers with infl ammatory markers and components 
of metabolic syndrome
Femoral BMD Vertebral BMD Osteocalcin B-CTx
Waist circumference Correlation
coeffi  cient
0.3616 0.2385 -0.2693 -0.3359
p-value 0.001 0.027 0.011 0.002
Insulin Correlation
coeffi  cient
0.02981 0.0126 -0.2439 -0.2239
p-value 0.005 0.908 0.021 0.037
PAI-1 Correlation
coeffi  cient
0.345 0.1487 -0.2809 -0.2653
p-value 0.001 0.172 0.007 0.012
CRP Correlation
coeffi  cient
0.2928 0.0952 -0.0185 -0.1088
p-value 0.116 0.395 0.096 0.331
Fibrinogen Correlation
coeffi  cient
0.318 0.331 0.0230 0.0313
p-value 0.774 0.765 0.831 0.775
BMD = bone mineral density; B-CTx = beta-CrossLaps; PAI-1 = plasminogen activator inhibitor-1; CRP = C-reactive protein
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pressed as a result of hyperinsulinemia present in pa-
tients with visceral obesity, thus blocking bone resorp-
tion leading to higher femoral BMD.
Spearman’s correlation yielded a strongly signifi -
cant negative association of B-CTx and OC with 
waist circumference, insulin levels and PAI-1 (Table 
2), also indicating supression of bone turnover rate due 
to hyperinsulinemia. Furthermore, there was no corel-
lation between infl ammation markers (CRP and fi -
brinogen) and bone turnover markers. Total femoral 
BMD was signifi cantly positively associated with 
waist circumference, insulin levels and PAI-1, while 
vertebral BMD correlated signifi cantly only with waist 
circumference (Table 2). Th ere was no correlation with 
CRP or fi brinogen.
Discussion
Although it is generally accepted that obesity has a 
protective eff ect on bone tissue, some studies have re-
vealed the opposite, i.e. that obesity is not benefi cial or 
has a negative eff ect on osteoporosis. In a study of 
postmenopausal Korean women19, waist circumfer-
ence, which provides an indication of central obesity 
(visceral fat mass), was related to low BMD and osteo-
porotic vertebral fractures. In contrast, our research 
demonstrated signifi cant positive correlation between 
vertebral and femoral BMD and waist circumference, 
which could be explained by higher circulating insulin 
levels in central obesity. Consequently, hyperinsu-
linemia signifi cantly correlated with higher femoral 
BMD, but was negatively associated with bone turn-
over markers, suggesting inhibition of bone resorption 
due to suppression of bone activity.
Diabetes mellitus type 2 is a condition that in-
cludes obesity, a factor associated with enhanced 
BMD, and infl ammation, a factor thought to reduce 
BMD, which could be present in all types of diabe-
tes20,21. However, low grade infl ammation is more se-
vere in subjects with high insulin resistance than in 
those with low insulin resistance22,23, presumably lead-
ing to reduced BMD in T2DM. Some studies have 
suggested that chronic infl ammation has a deleterious 
eff ect on BMD, resulting in development of osteopo-
rosis14,24. Th erefore, T2DM has a potential dual eff ect 
on bone health, i.e. protective eff ect due to obesity and 
adverse one as a result of bone resorption activated by 
chronic infl ammation.
Whereas previous work suggests that osteoporosis 
is linked to infl ammation, it is not yet clear whether 
higher CRP levels are associated with bone loss15. In a 
recently published study, CRP was associated inversely 
with composite strength index, but was not associated 
with femoral neck or lumbar spine BMD25, which is 
consistent with our observation. Th e only infl amma-
tion marker linked with higher femoral BMD was 
PAI-1, a recognized modulator of matrix implicated in 
the regulation of bone homeostasis. Over-expression 
of PAI-1 in transgenic mice resulted in increased min-
eralization and biomechanical properties of mouse 
femora26. In a study performed on PAI-1 knockout 
mice, PAI-1 (and potentially the plasminogen extra-
cellular matrix protease system) was demonstrated to 
be an important regulator of bone size during develop-
mental growth, playing a regulatory role in the deter-
mination of fracture callus size, cartilage formation, 
and resorption during bone fracture repair27. PAI-1 
also negatively correlated with bone turnover markers, 
once again suggesting higher mineral density as a re-
sult of inhibited bone resorption. In a recently pub-
lished study increased PAI levels were associated with 
higher BMD in obese diabetic female patients impli-
cating direct involvement in bone metabolism28.
Total femoral BMD was signifi cantly higher in the 
overweight group, whereas no signifi cant diff erence in 
the vertebral BMD was noted, implying that the ef-
fects of obesity and hyperinsulinemia on BMD varied 
by anatomic site, as shown in previous studies29.
Our study had some limitations. Since our data 
were cross-sectional, we had a limited ability to assess 
temporal relationship between the components of 
metabolic syndrome and BMD. Further longitudinal 
studies are needed to elucidate the association between 
bone and energy metabolism.
Th ese fi ndings suggest that the protective eff ect of 
the metabolic syndrome components, i.e. abdominal 
obesity and hyperinsulinemia in T2DM could prevail 
over deleterious eff ect of chronic infl ammation on 
bone metabolism, thus resulting in increased total 
femoral BMD.
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Sažetak
POVEZANOST KOŠTANE MINERALNE GUSTOĆE I SASTAVNICA METABOLIČKOG SINDROMA 
U POSTMENOPAUZALNIH ŽENA SA ŠEĆERNOM BOLEŠĆU TIPA 2
I. Bilić-Ćurčić, S. Makarović, I. Mihaljević, M. Franceschi i T. Jukić
Šećerna bolest tipa 2 povezana je s većom koštanom mineralnom gustoćom (bone mineral density, BMD) zbog debljine, 
iako se zamijećeni ubrzani gubitak koštane mase tijekom vremena može objasniti prisustvom kronične upale. Cilj ovoga 
istraživanja bio je utvrditi povezanost biljega koštane pregradnje i koštane gustoće s centralnom debljinom, hiperinzulinemi-
jom kao i upalnim biljezima u postmenopauzalnih žena sa šećernom bolešću tipa 2. U 114 ispitanica izmjerena je koštana 
gustoća kralježnice i kuka, određeni su osteokalcin, pirilinks D, beta-CrossLaps (B-CTx), inzulin, C-reaktivni protein (CRP), 
fi brinogen i inhibitor aktivatora plazminogena-1 (PAI-1). Ispitanice slične dobi, podjednakog trajanja dijabetesa te HbA1c 
bile su podijeljene u dvije skupine prema indeksu tjelesne mase (ITM): niži ili jednaki 27 kg/m2 (31 ispitanica) te veći od 27 
kg/m2 (83 ispitanice). Niže vrijednosti osteokalcina (p=0,001), B-CTx (p=0,000007) i pirilinksa D (p=0,0365) te više vrijed-
nosti košane gustoće kuka (p=0,00006), inzulina (p=0,0002), PAI-1 (p=0,0000) i CRP (p=0,002) utvrđene su u skupini s 
prekomjernom tjelesnom težinom. Nije bilo statistički značajne razlike u koštanoj gustoći kralježnice i vrijednosti fi brino-
gena. Osteokalcin i B-CTx su negativno korelirali, dok je BMD kuka bio u pozitivnoj korealciji s opsegom struka, inzulinom 
i PAI-1. Ovi rezultati upućuju na to da sastavnice metaboličkog sindroma, centralna debljina i hiperinzulinemija utječu na 
povećanje koštane gustoće kuka inhibirajući koštanu pregradnju. Jedini upalni biljeg povezan s BMD kuka bio je PAI-1 koji 
povećava mineralizaciju kortikalne kosti na mišjem modelu.
Ključne riječi: Dijabetes melitus tip 2; Pretilost; Hiperinzulinemija; Upala; Kost, gustoća; Menopauza
